Status:
UNKNOWN
EFFECTS OF EXTRACORPOREAL CYTOKINE ELIMINATION ON HEMODYNAMIA AND MORTALITY IN CRITICAL PATIENTS
Lead Sponsor:
Hakan Küçükkepeci
Conditions:
Cytokine Hemadsorption Therapy in Critically Ill Patients Who Have no Microbiological Findings and Develop Vasoplegic Shock
Eligibility:
All Genders
18-80 years
Brief Summary
Observation of the effects of cytokine adsorbent hemadsorption therapy on hemodynamics and mortality in critically ill patients who developed vasoplegic shock due to hyperinflammation without microbio...
Detailed Description
Observation of the effects of cytokine adsorbent hemadsorption therapy on hemodynamics and mortality in critically ill patients who developed vasoplegic shock due to hyperinflammation without microbio...
Eligibility Criteria
Inclusion
- C-reactive protein (CRP) ≥ 100 mg/l
- Procalcitonin (PCT) \< 2 ng/l
- Patients aged 18-80 years who were treated with cytokine adsorption due to vasoplegic shock
Exclusion
- Patients under 18 years of age
- Patients with suspected or proven bacterial cause of vasoplegic shock.
- Those who did not approve to participate in the study
- Patients without vasoplegic shock
- Patients with CRP \< 100 mg/l, PCT ≥ 2 μg/L
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05984407
Start Date
August 1 2023
End Date
February 1 2024
Last Update
August 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prof. Dr. Cemil Taşcıoğlu City Hospital
Istanbul, Şişli, Turkey (Türkiye), 34384